Skip to main content
Salarius Pharmaceuticals, Inc. logo

Salarius Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SLRX ISIN · US79400X4043 LEI · 549300CLUMLZXIHU7X22 US Professional, scientific and technical activities
Open in API
Filings indexed 702 across all filing types
Latest filing 2018-07-26 Director's Dealing
Country US United States of America
Listing US SLRX

About Salarius Pharmaceuticals, Inc.

https://salariuspharma.com/

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for cancer patients with high unmet medical needs. The company's core technology focuses on correcting the dysregulated gene expression of cancer cells, a key driver of disease development. Its pipeline includes two classes of drugs: targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs). The lead TPI candidate, seclidemstat (SP-2577), is in Phase 1/2 clinical trials, while the lead TPD candidate, SP-3164, is in IND-enabling studies. These therapeutic candidates are being developed to treat solid and hematologic cancers, including leukemias and lymphomas.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2018-07-26 English
FORM 4
Director's Dealing
2018-07-26 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated July 23, 2018, for Flex Pharma, Inc. The key content is under Item 5.02, which reports the departure of a director, Roderick MacKinnon, from the company's Board of Directors. There is no financial data or report attached; the document is an announcement of a management change. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 2800 characters, which is short and consistent with a regulatory announcement rather than a full report. Therefore, the correct classification is MANG with high confidence.
2018-07-25 English
8-K/A
Regulatory Filings Classification · 95% confidence The document is a Form 8-K/A, which is an amendment to a Current Report filed with the SEC. It reports on corporate restructuring plans, severance and retention costs, and executive retention arrangements. It does not contain comprehensive financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). It also does not fit categories like Earnings Release or Management Reports. The document is a regulatory filing updating investors and the SEC about material corporate events and agreements. Therefore, it fits best under Regulatory Filings (RNS). The document length (8443 characters) and content confirm it is not merely an announcement but a substantive regulatory update, yet not a full financial report.
2018-06-20 English
FORM 4
Director's Dealing
2018-06-18 English
FORM 4
Director's Dealing
2018-06-18 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.